Treating Depression Reduces Medicare Costs; Provider Challenges Remain

  • This page as PDF

Summary

A recent Avalere analysis of Medicare Fee-for-Service (FFS) data illustrates that treating major depressive disorder (MDD) in Medicare-eligible beneficiaries results in a 4% reduction in total cost compared to untreated patients, highlighting the importance of incentivizing adequate provider supply and payment in the geriatric psychiatry market.

Behavioral health treatment has received growing attention in recent years as a method of both improving patient quality of life and reducing healthcare costs. Notably, while the Medicare-eligible population is expected to grow by 55% through 2030, the supply of geriatric psychiatrists remains inadequate and is contracting, with an estimated national average of only 2.6 geriatric psychiatrists per 100,000 state population aged 65 and older⁴. A recent Avalere analysis of Medicare FFS data illustrates that treating MDD in Medicare-eligible beneficiaries results in a 4% reduction in total cost compared to untreated patients, highlighting the importance of incentivizing adequate provider supply and payment in the geriatric psychiatry market.

Current Provider and Payment Environment

Based on an analysis of the American Medical Association Physician Masterfile, the University of Michigan Behavioral Health Workforce Research Center assessed the distribution of the US psychiatric subspecialist workforce.

The analysis focused on several different state and country aspects of psychiatric supply, though the most notable findings highlight the supply of psychiatric providers per affected population across relevant age and payer groups. The pertinent number of providers per age group is:

  • A national average of 12.9 general psychiatrists per 100,000 state population
  • A national average of 14.9 child and adolescent psychiatrists per 100,000 state population under the age of 18
  • A national average of only 2.6 geriatric psychiatrists per 100,000 state population aged 65 and older

With this relative dearth of geriatric providers in mind, it is also important to highlight recent trends in mental health procedure payments and general inflation, which illustrate:

  • An average annual Medicare FFS physician payment rate increase of 1.2% across 10 common mental health related codes, from 2017 to 2022 (Medicare Physician Fee Schedule, 2017–2022; individual CPT codes included in Table 1)
  • An average rate of inflation of 2.5% from 2017 to 2021
  • A recent Avalere survey, in which private health plans cited low reimbursement rates for behavioral health services as a key barrier in establishing and maintaining behavioral health network adequacy

In aggregate, these figures highlight the relative lack of geriatric focused providers compared to general psychiatrists, as well as the modest if inadequate payment updates under Medicare FFS when compared to rates of inflation.

Avalere Analysis of Treatment Cost Impact

To assess the impact of behavioral health treatment in the Medicare population, Avalere leveraged the 100% Medicare FFS data file (accessed via a research-focused data use agreement with the Centers for Medicare & Medicaid Services) to evaluate how cost and outcomes for Medicare patients with newly diagnosed MDD compared, leveraging 2 comparable cohorts that either did or did not receive behavioral health treatment.

The goal of the assessment was to evaluate and characterize how behavioral health treatment (or non-treatment) impacted beneficiary cost when comparing a 24-month follow up period to a 12-month baseline period.

Figure 1. PMPM Cost Comparison of Treated and Untreated Populations, Follow-up Period Compared to Baseline Period
Figure 1. PMPM Cost Comparison of Treated and Untreated Populations, Follow-up Period Compared to Baseline Period

In comparing treated and untreated patient populations over the baseline and follow-up periods:

  • Total treated per member per month (PMPM) costs declined 10%, compared to the untreated PMPM costs declining only 6%
  • Treated PMPM medical costs declined by 5%, while untreated medical costs were unchanged
  • Treated PMPM hospital costs declined by 5%, while untreated hospital costs increased by 10%
  • Treated PMPM emergency department costs declined by 8%, while untreated emergency department costs increased by 1%

In total, Avalere’s analysis suggests that mental health treatment for Medicare beneficiaries with newly diagnosed MDD can improve beneficiary costs across several metrics of total, medical, hospital, and emergency department related costs.

Outlook

Avalere’s analysis highlights the positive impact that mental health treatment can have on Medicare FFS patient costs for certain patient populations, and further illustrates the need for Medicare payment stability in attracting providers to serve the geriatric psychiatry market.

To receive Avalere updates, connect with us.

Supporting Material

Table 1. Medicare FFS Non-Facility Physician Payment Rates, Select Mental Health Procedures, 2017–2022
HCPCS Descriptor 2017 2018 2019 2020 2021 2022
90791 Psychological diagnostic evaluation $132.07 $136.08 $140.19 $145.44 $180.75 $173.66
90832 Psychological treatment with patient, 30 minutes $64.24 $66.24 $68.47 $71.10 $77.81 $75.58
90834 Psychological treatment with patient, 45 minutes $85.42 $88.56 $91.18 $94.55 $103.28 $99.76
90837 Psychological treatment with patient, 60 minutes $128.12 $132.48 $136.95 $141.47 $152.48 $146.45
90838 Psychological treatment with patient, w e/m, 60 min $111.25 $115.56 $118.57 $121.26 $119.33 $114.88
90846 Family psychological treatment without patient, 50 min $103.36 $106.92 $110.28 $103.58 $99.10 $95.40
90847 Family psychological treatment with patient, 50 min $107.31 $111.24 $114.60 $107.19 $102.59 $98.75
90853 Group psychotherapy $25.84 $26.64 $27.39 $28.15 $27.57 $26.54
90875 Psychophysiological therapy $62.45 $64.08 $64.87 $63.52 $62.11 $59.79
99404 Preventive counseling, individual $112.69 $114.84 $115.69 $116.93 $114.80 $111.18
Table 2. Inflation Rate, 2017–2021
(2021 data include Q2 2020 to Q2 2021)
2017 2018 2019 2020 2021
Inflation Rate 2.1% 2.4% 1.8% 1.2% 4.8%
Table 3. Medicare Eligible Population in Millions, 2017–2021
2017 2018 2019 2020 2021
Population 56.8 58.2 59.8 61.2 62.7
Webinar | Valuing the Patient Perspective: Patient-Centered HTA Our expert panel addressed the challenge of integrating patient perspectives into value assessments, discussing implications for evidence strategy, health equity, caregiver involvement, and downstream impacts on care delivery.
Learn More
Watch the Replay
From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about RWE and Patient-Centered Outcomes
Please enter your email address to be notified when new RWE and Patient-Centered Outcomes insights are published.

Back To Top